Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
AstraZeneca
Moodys
Johnson and Johnson
Mallinckrodt

Last Updated: May 21, 2022

CLINICAL TRIALS PROFILE FOR BETAMETHASONE SODIUM PHOSPHATE


✉ Email this page to a colleague

« Back to Dashboard

505(b)(2) Clinical Trials for Betamethasone Sodium Phosphate

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
OTC NCT03707795 ↗ Treatment of FUS-Related ALS With Betamethasone - The TRANSLATE Study Completed Edward Kasaraskis Early Phase 1 2017-08-21 By doing this study the investigator hopes to learn more about a potential cause of amyotrophic lateral sclerosis (ALS) called "oxidative stress". Oxidative stress is essentially an imbalance between the production of certain chemicals in the body called "free radicals" and the ability of the body to counteract or detoxify their harmful effects through neutralization by antioxidants. It is thought that factors such as environmental exposure (chemicals and lead), diet, smoking,alcohol consumption, physical activity and psychological stress cause oxidative stress to occur inside the body. By doing this study, the investigator hopes to learn whether the FDA-approved steroid medication called Betamethasone will restore overall antioxidant activity fALS patients with mutations in the Fused in Sarcoma gene (FUS gene). Participants who agree to take part in this research study, agree to the following responsibilities: - Attend all scheduled visits - Notify the study doctor of any illnesses, unexpected or troublesome side effects, or any other medical problems that occur during the study - Be completely honest with their answers to all questions - Check with the study doctor before taking any new medications, whether prescribed or "over the counter," even vitamins and herbal supplements.
OTC NCT03707795 ↗ Treatment of FUS-Related ALS With Betamethasone - The TRANSLATE Study Completed University of Kentucky Early Phase 1 2017-08-21 By doing this study the investigator hopes to learn more about a potential cause of amyotrophic lateral sclerosis (ALS) called "oxidative stress". Oxidative stress is essentially an imbalance between the production of certain chemicals in the body called "free radicals" and the ability of the body to counteract or detoxify their harmful effects through neutralization by antioxidants. It is thought that factors such as environmental exposure (chemicals and lead), diet, smoking,alcohol consumption, physical activity and psychological stress cause oxidative stress to occur inside the body. By doing this study, the investigator hopes to learn whether the FDA-approved steroid medication called Betamethasone will restore overall antioxidant activity fALS patients with mutations in the Fused in Sarcoma gene (FUS gene). Participants who agree to take part in this research study, agree to the following responsibilities: - Attend all scheduled visits - Notify the study doctor of any illnesses, unexpected or troublesome side effects, or any other medical problems that occur during the study - Be completely honest with their answers to all questions - Check with the study doctor before taking any new medications, whether prescribed or "over the counter," even vitamins and herbal supplements.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Betamethasone Sodium Phosphate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00405496 ↗ Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis Completed Sirion Therapeutics, Inc. Phase 2 2000-03-01 The purpose of this phase 2 study is to determine if difluprednate ophthalmic emulsion is effective in the treatment of uveitis.
NCT00406887 ↗ Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis Completed Sirion Therapeutics, Inc. Phase 3 2002-08-01 The purpose of this phase 3 confirmatory study is to determine if difluprednate ophthalmic emulsion is effective in the treatment of treatment of uveitis.
NCT00542139 ↗ Evaluation of Diprospan Injection to the Knee on Rehabilitation of Patients After TKR of the Contralateral Knee Completed Hadassah Medical Organization Phase 4 2007-12-01 This study is performed to assess the influence of intraarticular injection of 2ml Diprospan (wich contains 4mg Betamethasone sodium phosphate and 10mg Betamethasone dipropionate) into osteoarthritic knee in patients who undergo a total knee replacement of their contralateral knee. The study population will include 50 patients with bilateral knee osteoarthritis, admitted for their first knee replacement surgery. Only patients with older than 50 years with primary osteoarthritis will be included. The patients will be randomized into 2 groups. Intervention group will receive an injection of 2ml Diprospan diluted in 10 ml Bupivocaine. The control group will receive an injection of 10ml of Bupivocaine. All patients will be followed after 6 weeks and three functional rehabilitation and pain scores will be assessed (VAS pain score, Timed Up and Go Score and Functional Ambulatory Category Scale).
NCT00914836 ↗ Comparison of 2 Doses of Corticosteroid Subacromial Injections for the Treatment of Painful Shoulder Withdrawn HaEmek Medical Center, Israel N/A 2009-06-01 The use of corticosteroid subacromial injections have been found to be effective for the treatment of shoulder pain. Higher doses may be better than lower doses for subacromial corticosteroid injection for rotator cuff tendonitis. The investigators aim this study to compare 2 doses of corticosteroids.
NCT00982332 ↗ Efficacy of Micro-Pulse Steroid Therapy as Induction Therapy in Patients With Polymyalgia Rheumatica Unknown status Bnai Zion Medical Center N/A 2010-03-01 The study will examine the efficacy of a single intramuscular injection of betamethasone dipropionate/betamethasone sodium phosphate at the dose of 20mg/8mg (injection volume 4 ml) as an induction therapy in patients with polymyalgia rheumatica. Twenty patients will be randomized to receive an injection of betamethasone or placebo (isotonic NaCl solution) immediately after diagnosis. Both groups will receive the standard-of-care steroid therapy, starting from 10 mg of prednisone every day (qd), tapered down by 2.5 mg monthly if the disease is not active (scheduled monthly follow-ups by a rheumatologist). Primary outcome measures: the total cumulative dose of glucocorticosteroids and disease duration.
NCT02066844 ↗ Navigator vs Standard Needle Injection for Hip Completed Cartiva, Inc. Phase 2 2014-02-01 The purpose of this randomized, parallel-group, single-blinded, single center, Phase II study is to collect data to compare the comfort and patient satisfaction of a hip injection delivered via the Navigator compared to a standard needle injection. In addition, delivery preparation will be compared between a Navigator injection and a standard hip injection. The data collected from this pilot study will serve as the basis to design a larger multi-center study.
NCT03446937 ↗ Effect of Antenatal Corticosteroids on Neonatal Morbidity. Completed Ahmadu Bello University Teaching Hospital N/A 2017-12-01 It will be a randomized controlled trial. There will be two study groups. Study group 1 will be given dexamethasone while study group 2 will be given betamethasone. The control group will be given placebo.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Betamethasone Sodium Phosphate

Condition Name

Condition Name for Betamethasone Sodium Phosphate
Intervention Trials
Dry Eye Disease 2
Anterior Uveitis 2
Scarring 1
Familial Amyotrophic Lateral Sclerosis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Betamethasone Sodium Phosphate
Intervention Trials
Keratoconjunctivitis Sicca 2
Eye Diseases 2
Uveitis, Anterior 2
Dry Eye Syndromes 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Betamethasone Sodium Phosphate

Trials by Country

Trials by Country for Betamethasone Sodium Phosphate
Location Trials
United States 33
Israel 3
Nigeria 1
Turkey 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Betamethasone Sodium Phosphate
Location Trials
California 3
New York 3
Kentucky 3
Georgia 2
Colorado 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Betamethasone Sodium Phosphate

Clinical Trial Phase

Clinical Trial Phase for Betamethasone Sodium Phosphate
Clinical Trial Phase Trials
Phase 4 2
Phase 3 2
Phase 2 4
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Betamethasone Sodium Phosphate
Clinical Trial Phase Trials
Completed 6
Not yet recruiting 2
Recruiting 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Betamethasone Sodium Phosphate

Sponsor Name

Sponsor Name for Betamethasone Sodium Phosphate
Sponsor Trials
Surface Pharmaceuticals, Inc. 2
Sirion Therapeutics, Inc. 2
Bnai Zion Medical Center 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Betamethasone Sodium Phosphate
Sponsor Trials
Other 9
Industry 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Medtronic
Johnson and Johnson
Colorcon
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.